Pharmaceutical

Express Scripts cuts payments for customized drugs

July 3, 2014
Associated Press
The nation's largest pharmacy benefit manager, Express Scripts, is dramatically scaling back its coverage of compounded medications, saying most of the custom-mixed medicines are ineffective or overpriced.
More

Lilly wins EU backing for version of insulin drug

June 27, 2014
Bloomberg News
Lantus, which garnered $7.8 billion in sales for Paris-based Sanofi in 2013, loses patent protection in Europe in May next year.
More

Merck's exit pushes Endocyte shares lower

June 18, 2014
 IBJ Staff
Shares of Endocyte Inc. skidded 15 percent Wednesday after industry giant Merck & Co. Inc. decided it would give up on developing Endocyte cancer drug vintafolide.
More

Lilly, IU expect $25M plan to create new model for drug R&D

June 16, 2014
J.K. Wall
A new research consortium spearheaded by the Indiana University School of Medicine and Eli Lilly and Co. could bring in $25 million to $50 million over five years to create a new approach for developing drugs that provide more precise treatment for small groups of patients.
More

Doctors want to improve state drug-tracking system

June 9, 2014
Associated Press
A study has found that most doctors in Indiana aren't frequently using an electronic system designed to detect prescription drug abuse.
More

Glaxo to pay $105 million in multistate settlement

June 4, 2014
Bloomberg News
Indiana will receive part of the settlement money. The accord will prohibit Glaxo from providing incentive payments to salespeople that encourage uses of the drugs not indicated on their labels.
More

Lilly, Sanofi seek to sell erection drug Cialis without prescription

May 28, 2014
 Bloomberg News and IBJ Staff
Sanofi will apply for approval of Cialis as an over-the-counter treatment in the United States, Europe, Canada and Australia. The drug garnered $2.16 billion in sales last year.
More

Pfizer pulls plug on push to buy AstraZeneca

May 26, 2014
Associated Press
Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the industry's history.
More

Takeda denies hiding Actos cancer risks in Nevada trial

May 21, 2014
Associated Press
Takeda Pharmaceutical Co. didn’t hide the alleged bladder-cancer risks of its diabetes medicine Actos, a lawyer for the company told a jury. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
More

Drugmaker hid diabetes drug’s cancer risks, lawyer says

May 19, 2014
Bloomberg News
Takeda Pharmaceutical Co. executives covered up the cancer risks of its diabetes medicine Actos to protect billions of dollars in sales, a lawyer for two women argued.
More

Lilly's latest sales strategy: the soft sell

May 17, 2014
J.K. Wall
Eli Lilly and Co. thinks it has a secret weapon to return to growth. No, it’s not a new blockbuster drug—although Lilly will most likely have several new products hit the market this year and next. Rather, it’s an unorthodox, softer approach put into play by its U.S. sales force.
More

Lilly loses patent dispute over Alimta in London court

May 15, 2014
Bloomberg News
Eli Lilly and Co. lost a United Kingdom lawsuit over its Alimta cancer treatment when a judge ruled Thursday that a generic version planned by Actavis Plc doesn't breach European patents.
More

Lilly to appeal $450M ruling over poisoned workers in Brazil

May 12, 2014
 IBJ Staff
Brazilian federal prosecutors had accused a Lilly subsidiary of incinerating toxic waste at the plant that it operated until 2003.
More

Lilly says its once-daily insulin tops competitor's drug

May 12, 2014
Bloomberg News
Eli Lilly & Co. said its experimental insulin helped diabetic patients more than Sanofi’s biggest product in studies that also raised some safety risks.
More

Bayer’s $14.2 billion Merck buy shows pharma strategy split

May 7, 2014
Bloomberg News
Bayer AG's $14.2 billion acquisition of Merck & Co. is the latest in a series of big pharma deals and it exposes a deepening split in the way drugmakers approach their portfolios.
More

Endocyte shares plunge 60 percent after drug trial is stopped

May 2, 2014
 Bloomberg News and IBJ Staff
Endocyte Inc.'s stock fell more than 60 percent in early trading Friday after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer.
More

Drug prices surge as generics, niche treatments eat profit

May 1, 2014
Bloomberg News
Since 2007, the cost of brand-name medicines has jumped, with prices doubling for dozens of established drugs that target everything from multiple sclerosis to cancer, blood pressure and even erections, according to an analysis conducted for Bloomberg News.
More

Roche battles payment cuts while growing diagnostics business

April 28, 2014
J.K. Wall

Life Sciences Burris
                           interview Watch VideoNew tests have helped Roche Diagnostics grow its North American revenue, excluding its troubled diabetes care business, 23 percent over the past five years. But the money for diagnostic tests continues to go down in key areas, noted CFO Wayne Burris.

More

Lilly to pay dearly for Novartis animal health biz

April 22, 2014
J.K. Wall
Wall Street analysts raised their eyebrows at the hefty price Eli Lilly and Co. will pay to acquire Novartis Animal Health, when compared to the value of the biggest player in the field.
More

Blockbuster deal: Eli Lilly paying $5.4B for Novartis Animal Health

April 22, 2014
 IBJ Staff
Eli Lilly and Co. has agreed to pay $5.4 billion for Novartis Animal Health in the second-largest deal in the company's history. The acquisition is part of a blockbuster three-way drug deal.
More

Lilly wins approval for potential blockbuster drug

April 21, 2014
Bloomberg News
The Indianapolis-based pharmaceutical maker gets a much-needed boost with FDA approval for gastric-cancer drug ramucirumab, which quickly could account for $1 billion in annual sales.
More

Endocyte raises another $100M in stock offering

April 7, 2014
J.K. Wall
Another public stock offering by the West Lafayette-based drugmaker swells its war chest for cancer drug development to $225 million.
More

Pfizer, Lilly drugs slow advanced breast cancer in studies

April 7, 2014
Bloomberg News
Pfizer Inc., Eli Lilly and Co. and Novartis AG have dug an idea out of the pharmaceutical dustbin to create new medicines that are showing blockbuster potential.
More

Would-be Lilly foe wins U.S. panel backing for inhaled insulin

April 1, 2014
Bloomberg News
Advisers to the Food and Drug Administration voted 13-1 and 14-0 that the drug, Afrezza, should be approved for Type 1 and Type 2 diabetes, respectively. The FDA doesn’t have to follow the panel’s recommendation.
More

Cancer treatment makes Endocyte premium takeover target

March 28, 2014
Bloomberg News
Now that Indiana-based Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
More
Page  1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am a Lyft driver who is a licensed CDL professional driver. ALL Lyft drivers take pride in providing quality service to the Indianapolis and surrounding areas, and we take the safety of our passengers and the public seriously.(passengers are required to put seat belts on when they get in our cars) We do go through background checks, driving records are checked as are the personal cars we drive, (these are OUR private cars we use) Unlike taxi cabs and their drivers Lyft (and yes Uber) provide passengers with a clean car inside and out, a friendly and courteous driver, and who is dressed appropriately and is groomed appropriately. I go so far as to offer mints, candy and/or small bottle of water to the my customers. It's a mutual respect between driver and passenger. With Best Regards

  2. to be the big fish in the little pond of IRL midwest racin' when yer up against Racin' Gardner

  3. In the first sentance "As a resident of one of these new Carmel Apartments the issue the local governments need to discuss are build quality & price." need a way to edit

  4. As a resident of one of these new Carmel Apartments the issue the local governments need to discuss is build quality & price. First none of these places is worth $1100 for a one bedroom. Downtown Carmel or Keystone at the Crossing in Indy. It doesn't matter. All require you to get in your car to get just about anywhere you need to go. I'm in one of the Carmel apartments now where after just 2.5 short years one of the kitchen cabinet doors is crooked and lawn and property maintenance seems to be lacking my old Indianapolis apartment which cost $300 less. This is one of the new star apartments. As they keep building throughout the area "deals" will start popping up creating shoppers. If your property is falling apart after year 3 what will it look like after year 5 or 10??? Why would one stay here if they could move to a new Broad Ripple in 2 to 3 years or another part of the Far Northside?? The complexes aren't going to let the "poor" move in without local permission so that's not that problem, but it the occupancy rate drops suddenly because the "Young" people moved back to Indy then look out.

  5. Why are you so concerned about Ace hardware? I don't understand why anyone goes there! Every time ive gone in the past, they don't have what I need and I end up going to the big box stores. I understand the service aspect and that they try to be helpful but if they are going to survive I think they might need to carry more specialty parts.

ADVERTISEMENT